News and Events

Subscribe to our press distribution list to receive the latest news about AMW.

Upcoming

Events

No events available

Past

Events

Archive

Pharmapack

January 24-25, 2024 Paris, France https://www.pharmapackeurope.com/

Pharmasynergy

February 08-09, 2024
London, UK

euroPLX84

February 26-27, 2024 Lisbon, Portugal

BIO-Europe Spring

March 18-20, 2024
Barcelona, Spain
https://informaconnect.com/bioeurope-spring/

4th Wet AMD & Diabetic Eye Disease Drug Development

March 19-21, 2024
Boston, MA
https://wet-amd-drug-development.com/

BIO International Convention

June 03-06, 2024
San Diego, California
https://www.bio.org/events/bio-international-convention

CPHI South East Asia

July 10-12, 2024 Bangkok, Thailand https://www.cphi.com/sea/en/home.html

CPHI 2024

October 08-10, 2024 Milan, Italy https://www.cphi.com/europe/en/home.html

PODD – Partnership Opportunities in Drug Delivery

October 28-29, 2024 Boston, USA https://poddconference.com

BIO-Europe

November 04-06, 2024 Stockholm, Sweden https://informaconnect.com/bioeurope/

Latest

News

9. November 2021

AMW and AdhexPharma announce strategic partnership for transdermal delivery systems

Today a strategic partnership between AMW GmbH and AdhexPharma SAS on AMW’s transdermal delivery systems technology platform and product portfolio was announced, combining the strengths of both companies in the field of TDS. Under the partnership, AMW will focus on development, marketing authorization and licensing of novel transdermal delivery systems. AdhexPharma will focus on the commercial manufacturing and lifecycle management of the products. AdhexPharma will take over the manufacturing equipment and the IP for AMW’s products Buprenorphine and Rivastigmine and following a transition phase of up to 30 months the contract manufacturing of these Products from AMW.

19. October 2021

AMW signs license and supply agreements for the commercialization of its goserelin and leuprorelin implants in Israel

AMW GmbH, a specialty pharmaceutical company focused on innovative drug delivery systems, announced today that license and supply agreements (LSAs) have been signed with an undisclosed partner for the commercialization of its goserelin and leuprorelin implants in Israel.

22. May 2021

AMW signs License and Supply Agreement for Commercialization of Goserelin Implant in a LATAM Country

AMW GmbH, a specialty pharmaceutical company focused on innovative drug delivery systems, today announces that it has entered into a license and supply agreement (LSA) with an undisclosed partner for the commercialization of its goserelin implant in a relevant LATAM country. AMW’s new LATAM partner is active and highly experienced in the registration and commercialization of pharmaceutical products and will help to bring improved medication to patients.

15. March 2021

AMW GmbH expands management team and appoints Dr. Konstantin Petropoulos as Chief Executive Officer

AMW GmbH announced today that Dr. Konstantin Petropoulos has been appointed Chief Executive Officer (CEO) effective March 15, 2021 This expands Dr. Friedrich Tegel and Philipp Karbach to the existing management team.

11. March 2021

EMPLOYEES OF AMW DONATE THE PROCEEDS OF THE TOMBOLA IN THE AMOUNT OF 500 EURO

Employees of AMW GmbH, a globally active pharmaceutical company based in Warngau, donate the proceeds from a tombola to Holzkirchen.

For press and news inquiries please send an e-mail to news@a-m-w.eu